GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Drug: Placebo
Biological: HZ/su

First Posted Date: 2022-02-02

Last Posted Date: 2024-04-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 288

Registration Number: NCT05219253

Locations: 🇮🇳
GSK Investigational Site, Pune, India

Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

Phase 1

Completed

Conditions: Pain

Interventions: Drug: GSK3858279
Drug: Placebo

First Posted Date: 2021-12-30

Last Posted Date: 2023-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT05174013

Locations: 🇦🇺
GSK Investigational Site, Melbourne, Victoria, Australia

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

Phase 3

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Combination Product: RSV MAT vaccine
Combination Product: dTpa vaccine

First Posted Date: 2021-12-27

Last Posted Date: 2023-04-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 9

Registration Number: NCT05169905

Locations: 🇺🇸
GSK Investigational Site, Beaumont, Texas, United States

Study of GSK3511294 in Healthy Chinese Participants

Phase 1

Completed

Conditions: Asthma

Interventions: Biological: GSK3511294

First Posted Date: 2021-12-01

Last Posted Date: 2023-02-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT05140200

Locations: 🇨🇳
GSK Investigational Site, Hangzhou, Zhejiang, China

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Phase 1

Recruiting

Conditions: Uncomplicated Urinary Tract Infections
Urinary Tract Infections

Interventions: Drug: GSK3882347
Drug: Nitrofurantoin
Drug: Placebo

First Posted Date: 2021-12-01

Last Posted Date: 2024-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 122

Registration Number: NCT05138822

Locations: 🇺🇸
GSK Investigational Site, Missouri City, Texas, United States

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

Phase 1

Completed

Conditions: Pruritus

Interventions: Drug: Obeticholic acid
Drug: Linerixibat

First Posted Date: 2021-11-24

Last Posted Date: 2022-11-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 52

Registration Number: NCT05133830

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: GSK3888130B
Drug: Placebo

First Posted Date: 2021-11-23

Last Posted Date: 2024-03-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT05131971

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Phase 2

Terminated

Conditions: COVID-19

Interventions: Biological: Sotrovimab

First Posted Date: 2021-11-17

Last Posted Date: 2024-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 8

Registration Number: NCT05124210

Locations: 🇺🇸
GSK Investigational Site, Mesa, Arizona, United States

Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

Phase 2

Terminated

Conditions: Neoplasms

Interventions: Other: Screening Platform

First Posted Date: 2021-10-29

Last Posted Date: 2024-02-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT05100316

Locations: 🇺🇸
GSK Investigational Site, Springfield, Missouri, United States

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Cytomegalovirus Infections

Interventions: Biological: Pentamer (low)/gB(low)/Adjuvant vaccine
Combination Product: Placebo (saline)
Biological: Pentamer (med)/gB(low)/Adjuvant vaccine
Biological: Pentamer (med)/gB(med)/Adjuvant vaccine
Biological: Pentamer (high)/gB(med)/Adjuvant vaccine

First Posted Date: 2021-10-22

Last Posted Date: 2024-02-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 329

Registration Number: NCT05089630

Locations: 🇺🇸
GSK Investigational Site, Puyallup, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy